Skip to content

Frequency Foundation

Twice the Energy with Half the Stress

Aerosol Infection by Flu Viruses

Photo by Kickstarter Michael Gilvary Sick Building Project – view here

For years Frequency Foundation has been reporting on flu virus aerosol infection. Many of these infections are caused by airborne parasites where masks can block large particles. However, for virus particles of a few microns, masks are ineffective. This came to a head in COVID when it became clear that medical scientists do not understand basic physics. See https://www.wired.com/story/the-teeny-tiny-scientific-screwup-that-helped-covid-kill/

Frequencies are mathematic data that do not lie. They are present in a building or not. Frequencies sent to the building consistently reduce infection 100% of the time. You do not need a clinical trial to show this after you do it on hundreds of buildings with 100% success (in at least reducing infection if not eliminating it).

Furthermore, if you are skeptical, it only takes a few weeks on your building to prove it either helps or does not help. The alternative is to live with the infection continuously.

Conventional flus, spread by aerosol parasites, were radically reduced during COVID with masks, despite the propaganda masks were ineffective in stopping the COVID virus. The 6 foot separation was also a myth that has been debunked in the science journals. Do your own research. There is real data out there.

Here we just want to emphasize that aerosol infection is one of the primary routes of viral infection, particularly for COVID, and buildings that are not properly ventilated with air cleaners that kill viruses become infected. There are many companies that do sick building remediation but they are expensive and your local Starbucks, Whole Foods, Home Depot, and other vendors are not using them every week. A single really sick person can infect a store that does not have air clearers and ventilation that kill viruses and other pathogens quickly.

This is why we have the “Sick Building Service” for weekly scans for $99/month. We have many individual subscribers for home that are infected as people are well aware that mold is a critical issue. When we scan buildings using the same technology we use for people we find viruses, bacteria, and many other things in addition to mold. It is so inexpensive that some of our homes use this service every month, continuously.

It is critical for health clinics and restaurants to be aware of the Sick Building Service because these are the areas that become most infected, most often, by the most people. We find the same thing in retail and wholesale stores. Clearing these buildings with frequencies not only prevents infection of customers and employees, it significantly changes the atmosphere in the store make it feel more friendly. People linger longer and buy more products as one of the largest retail furniture outlets in Hawaii discovered.

Mycoplasma Fementans Incognitus Frequencies Version 1.0

United States Patent 5,242,820
Lo September 7, 1993

Pathogenic Mycoplasma (Mycoplasma Fermentans Incognitus)

Abstract
The invention relates to a novel pathogenic mycoplasma isolated from patients with Acquired Immune Deficiency Syndrome (AIDS) and its use in detecting antibodies in sera of AIDS patients, patients with AIDS-related complex (ARC) or patients dying of diseases and symptoms resembling AIDS diseases. The invention further relates to specific DNA sequences, antibodies against the pathogenic mycoplasma, and their use in detecting DNA or antigens of the pathogenic mycoplasma or other genetically and serologically closely related mycoplasmas in infected tissue of patients with AIDS or ARC or patients dying of symptoms resembling AIDS diseases. The invention still further relates to a variety of different forms of vaccine against mycoplasma infection in humans and/or animals.

Inventors: Lo; Shyh-Ching (Potomac, MD)
Assignee: American Registry of Pathology (Washington, DC)
Family ID: 27401851
Appl. No.: 07/710,361
Filed: June 6, 1991

Related U.S. Patent Documents

Application Number Filing Date Patent Number Issue Date
265920 Nov 2, 1988
875535 Jun 18, 1986

Other References

Marquart et al (1985) Mycoplasma-Like Structures . . . Eur J Clin Microbiol 4(1):73-74. .
Lo et al (1989) A Novel Virus-like Infectious Agent . . . Am J Trop Med Hyg 40(2):213-226. .
Lo et al (1989) Identification of M Incognitus . . . Am. J. Trop-Med. Hyg 41(5):601-616. .
Lo et al (1989) Association of the Virus-like Agent . . . Am J Trop Med Hyg 41(3):364-376. .
Lo et al (1989) Fatal Infection of Silvered Leaf Monkeys . . . Am. T Trop Med Hyg 40(4):399-409. .
Lo et al (1989) Virus-like Infectious Agent . . . Am J Trop Med Hyg 41(5):586-600. .
Marquart et al (Feb. 1985) Abstract Only Eur J Clin Microbiol 4(1):73-74. .
Hu et al (1990) Gene 93:67-72..

Primary Examiner: Nucker; Christine M.
Assistant Examiner: Preston; D. R.
Attorney, Agent or Firm: Venable, Baetjer, Howard & Civiletti

Government Interests
The invention described herein was made in the course of work under a grant or award from the United States Department of the Army.

Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a continuation-in-part of U.S. patent application Ser. No. 265,920, filed Nov. 2, 1988, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 875,535, filed Jun. 18, 1986, now abandoned.

Claims
What is claimed is:
1. A biologically pure mycoplasma isolated from tissues of patients with AIDS comprising the mycoplasma produced by the cell line ATCC No. CRL 9127.
2. A biologically pure mycoplasma having the identifying characteristics of M. fermentans incognitus, ATCC 53949.

Description
BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a novel strain of mycoplasma isolated from a patient with AIDS. The mycoplasma is closely related to a species of human mycoplasma, M. fermentans. Upon characterization of this mycoplasma, it may be classified as a unique strain within the species M. fermentans incognitus. This novel strain of nycoplasma is referred to hereinafter as the incognitus strain or M. fermentans incognitus.

The invention also relates to use of the mycoplasma M. fermentans incognitus as well as all strains of M. fermentans in detecting specific antibodies in sera of patients with AIDS or an acute fulminant systemic disease and/or animals and its use as a vaccine against infection by the mycoplasma. The invention further relates to incognitus strain-specific antibodies and cross-reactive which later break up into individual cells that are capable of passing through membrane filters of pore size 0.45 .mu.m or even 0.22 .mu.m.

Those with Lyme disease may already be aware of this coinfection. It appears to be circulating with the 2017 flu causing extended periods of serious illness. Frequencies are available to subscribers.